Cargando…
Fluoxetine regulates eEF2 activity (phosphorylation) via HDAC1 inhibitory mechanism in an LPS-induced mouse model of depression
BACKGROUND: Selective serotonin reuptaker inhibitors, including fluoxetine, are widely studied and prescribed antidepressants, while their exact molecular and cellular mechanism are yet to be defined. We investigated the involvement of HDAC1 and eEF2 in the antidepressant mechanisms of fluoxetine us...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7852137/ https://www.ncbi.nlm.nih.gov/pubmed/33526073 http://dx.doi.org/10.1186/s12974-021-02091-5 |
_version_ | 1783645760010584064 |
---|---|
author | Li, Weifen Ali, Tahir Zheng, Chengyou Liu, Zizhen He, Kaiwu Shah, Fawad Ali Ren, Qingguo Rahman, Shafiq Ur Li, Ningning Yu, Zhi-Jian Li, Shupeng |
author_facet | Li, Weifen Ali, Tahir Zheng, Chengyou Liu, Zizhen He, Kaiwu Shah, Fawad Ali Ren, Qingguo Rahman, Shafiq Ur Li, Ningning Yu, Zhi-Jian Li, Shupeng |
author_sort | Li, Weifen |
collection | PubMed |
description | BACKGROUND: Selective serotonin reuptaker inhibitors, including fluoxetine, are widely studied and prescribed antidepressants, while their exact molecular and cellular mechanism are yet to be defined. We investigated the involvement of HDAC1 and eEF2 in the antidepressant mechanisms of fluoxetine using a lipopolysaccharide (LPS)-induced depression-like behavior model. METHODS: For in vivo analysis, mice were treated with LPS (2 mg/kg BW), fluoxetine (20 mg/kg BW), HDAC1 activator (Exifone: 54 mg/kg BW) and NH125 (1 mg/kg BW). Depressive-like behaviors were confirmed via behavior tests including OFT, FST, SPT, and TST. Cytokines were measured by ELISA while Iba-1 and GFAP expression were determined by immunofluorescence. Further, the desired gene expression was measured by immunoblotting. For in vitro analysis, BV2 cell lines were cultured; treated with LPS, exifone, and fluoxetine; collected; and analyzed. RESULTS: Mice treated with LPS displayed depression-like behaviors, pronounced neuroinflammation, increased HDAC1 expression, and reduced eEF2 activity, as accompanied by altered synaptogenic factors including BDNF, SNAP25, and PSD95. Fluoxetine treatment exhibited antidepressant effects and ameliorated the molecular changes induced by LPS. Exifone, a selective HDAC1 activator, reversed the antidepressant and anti-inflammatory effects of fluoxetine both in vivo and in vitro, supporting a causing role of HDAC1 in neuroinflammation allied depression. Further molecular mechanisms underlying HDAC1 were explored with NH125, an eEF2K inhibitor, whose treatment reduced immobility time, altered pro-inflammatory cytokines, and NLRP3 expression. Moreover, NH125 treatment enhanced eEF2 and GSK3β activities, BDNF, SNAP25, and PSD95 expression, but had no effects on HDAC1. CONCLUSIONS: Our results showed that the antidepressant effects of fluoxetine may involve HDAC1-eEF2 related neuroinflammation and synaptogenesis. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12974-021-02091-5. |
format | Online Article Text |
id | pubmed-7852137 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-78521372021-02-03 Fluoxetine regulates eEF2 activity (phosphorylation) via HDAC1 inhibitory mechanism in an LPS-induced mouse model of depression Li, Weifen Ali, Tahir Zheng, Chengyou Liu, Zizhen He, Kaiwu Shah, Fawad Ali Ren, Qingguo Rahman, Shafiq Ur Li, Ningning Yu, Zhi-Jian Li, Shupeng J Neuroinflammation Research BACKGROUND: Selective serotonin reuptaker inhibitors, including fluoxetine, are widely studied and prescribed antidepressants, while their exact molecular and cellular mechanism are yet to be defined. We investigated the involvement of HDAC1 and eEF2 in the antidepressant mechanisms of fluoxetine using a lipopolysaccharide (LPS)-induced depression-like behavior model. METHODS: For in vivo analysis, mice were treated with LPS (2 mg/kg BW), fluoxetine (20 mg/kg BW), HDAC1 activator (Exifone: 54 mg/kg BW) and NH125 (1 mg/kg BW). Depressive-like behaviors were confirmed via behavior tests including OFT, FST, SPT, and TST. Cytokines were measured by ELISA while Iba-1 and GFAP expression were determined by immunofluorescence. Further, the desired gene expression was measured by immunoblotting. For in vitro analysis, BV2 cell lines were cultured; treated with LPS, exifone, and fluoxetine; collected; and analyzed. RESULTS: Mice treated with LPS displayed depression-like behaviors, pronounced neuroinflammation, increased HDAC1 expression, and reduced eEF2 activity, as accompanied by altered synaptogenic factors including BDNF, SNAP25, and PSD95. Fluoxetine treatment exhibited antidepressant effects and ameliorated the molecular changes induced by LPS. Exifone, a selective HDAC1 activator, reversed the antidepressant and anti-inflammatory effects of fluoxetine both in vivo and in vitro, supporting a causing role of HDAC1 in neuroinflammation allied depression. Further molecular mechanisms underlying HDAC1 were explored with NH125, an eEF2K inhibitor, whose treatment reduced immobility time, altered pro-inflammatory cytokines, and NLRP3 expression. Moreover, NH125 treatment enhanced eEF2 and GSK3β activities, BDNF, SNAP25, and PSD95 expression, but had no effects on HDAC1. CONCLUSIONS: Our results showed that the antidepressant effects of fluoxetine may involve HDAC1-eEF2 related neuroinflammation and synaptogenesis. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12974-021-02091-5. BioMed Central 2021-02-01 /pmc/articles/PMC7852137/ /pubmed/33526073 http://dx.doi.org/10.1186/s12974-021-02091-5 Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Li, Weifen Ali, Tahir Zheng, Chengyou Liu, Zizhen He, Kaiwu Shah, Fawad Ali Ren, Qingguo Rahman, Shafiq Ur Li, Ningning Yu, Zhi-Jian Li, Shupeng Fluoxetine regulates eEF2 activity (phosphorylation) via HDAC1 inhibitory mechanism in an LPS-induced mouse model of depression |
title | Fluoxetine regulates eEF2 activity (phosphorylation) via HDAC1 inhibitory mechanism in an LPS-induced mouse model of depression |
title_full | Fluoxetine regulates eEF2 activity (phosphorylation) via HDAC1 inhibitory mechanism in an LPS-induced mouse model of depression |
title_fullStr | Fluoxetine regulates eEF2 activity (phosphorylation) via HDAC1 inhibitory mechanism in an LPS-induced mouse model of depression |
title_full_unstemmed | Fluoxetine regulates eEF2 activity (phosphorylation) via HDAC1 inhibitory mechanism in an LPS-induced mouse model of depression |
title_short | Fluoxetine regulates eEF2 activity (phosphorylation) via HDAC1 inhibitory mechanism in an LPS-induced mouse model of depression |
title_sort | fluoxetine regulates eef2 activity (phosphorylation) via hdac1 inhibitory mechanism in an lps-induced mouse model of depression |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7852137/ https://www.ncbi.nlm.nih.gov/pubmed/33526073 http://dx.doi.org/10.1186/s12974-021-02091-5 |
work_keys_str_mv | AT liweifen fluoxetineregulateseef2activityphosphorylationviahdac1inhibitorymechanisminanlpsinducedmousemodelofdepression AT alitahir fluoxetineregulateseef2activityphosphorylationviahdac1inhibitorymechanisminanlpsinducedmousemodelofdepression AT zhengchengyou fluoxetineregulateseef2activityphosphorylationviahdac1inhibitorymechanisminanlpsinducedmousemodelofdepression AT liuzizhen fluoxetineregulateseef2activityphosphorylationviahdac1inhibitorymechanisminanlpsinducedmousemodelofdepression AT hekaiwu fluoxetineregulateseef2activityphosphorylationviahdac1inhibitorymechanisminanlpsinducedmousemodelofdepression AT shahfawadali fluoxetineregulateseef2activityphosphorylationviahdac1inhibitorymechanisminanlpsinducedmousemodelofdepression AT renqingguo fluoxetineregulateseef2activityphosphorylationviahdac1inhibitorymechanisminanlpsinducedmousemodelofdepression AT rahmanshafiqur fluoxetineregulateseef2activityphosphorylationviahdac1inhibitorymechanisminanlpsinducedmousemodelofdepression AT liningning fluoxetineregulateseef2activityphosphorylationviahdac1inhibitorymechanisminanlpsinducedmousemodelofdepression AT yuzhijian fluoxetineregulateseef2activityphosphorylationviahdac1inhibitorymechanisminanlpsinducedmousemodelofdepression AT lishupeng fluoxetineregulateseef2activityphosphorylationviahdac1inhibitorymechanisminanlpsinducedmousemodelofdepression |